XENON XE 133-V.S.S.
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XENON XE 133-V.S.S. (XENON XE 133-V.S.S.).
Xenon Xe-133 is a radioactive gas that emits beta and gamma radiation. It distributes to the lungs and is used for ventilation-perfusion imaging. Its mechanism is based on regional distribution in the lungs, reflecting ventilation. It does not have pharmacological activity.
| Metabolism | Inert gas; not metabolized. Excreted unchanged via the lungs (>95%) after inhalation. |
| Excretion | Eliminated almost entirely via exhalation through the lungs (>95%); negligible renal or biliary/fecal excretion. |
| Half-life | Terminal elimination half-life of approximately 3.5 minutes, corresponding to rapid washout from lungs following cessation of inhalation. |
| Protein binding | Negligible (<5%), not bound to plasma proteins. |
| Volume of Distribution | Approximately 4.5 L/kg, indicating extensive distribution into well-perfused tissues (brain, heart) due to high lipid solubility. |
| Bioavailability | 100% via inhalation; not administered by other routes. |
| Onset of Action | Immediate (within seconds) after inhalation, due to rapid diffusion into brain tissue. |
| Duration of Action | Very short, approximately 3-5 minutes post-inhalation; clinical effects dissipate quickly upon discontinuation. |
| Molecular Weight | 133 |
5-10 mCi (185-370 MBq) inhaled as a single dose for pulmonary ventilation imaging.
| Dosage form | GAS |
| Renal impairment | No dose adjustment required as Xenon Xe 133 is eliminated via exhalation. |
| Liver impairment | No dose adjustment required as Xenon Xe 133 is not hepatically metabolized. |
| Pediatric use | 0.3-0.5 mCi/kg (11.1-18.5 MBq/kg) inhaled, not to exceed 10 mCi (370 MBq). |
| Geriatric use | No specific adjustment; use lowest effective dose due to potential for diminished pulmonary function. |
| 1st trimester | Avoid unless benefit justifies risk; radioactive exposure may cause fetal harm. |
| 2nd trimester | Avoid unless benefit justifies risk; radioactive exposure may cause fetal harm. |
| 3rd trimester | Avoid unless benefit justifies risk; radioactive exposure may cause fetal harm. |
Clinical note
Comprehensive clinical and safety monograph for XENON XE 133-V.S.S. (XENON XE 133-V.S.S.).
| Placental transfer | Xenon-133 is a gas that can cross the placenta; limited data in humans, but animal studies show transfer. |
| Breastfeeding | Discontinue breastfeeding or temporarily interrupt for at least 24 hours after administration due to potential transfer of radioactive material. |
| Lactation Rating |
■ FDA Black Box Warning
None - Xenon Xe-133 is a diagnostic radiopharmaceutical; no FDA black box warning exists.
| Serious Effects |
Known hypersensitivity to any componentPregnancy (unless benefit clearly outweighs risk)
| Precautions | Radiation exposure risk; use only when diagnostic benefit outweighs risk, Pregnancy and lactation: consider alternatives due to potential fetal harm, Pediatric use: adjust dosage based on weight, Hypersensitivity reactions may occur but are rare |
| Food/Dietary | No known food interactions. No dietary restrictions required. Maintain normal hydration before procedure. |
| Clinical Pearls |
Loading safety data…
| Avoid |
| Teratogenic Risk | Xenon Xe 133 is a radioactive gas used for diagnostic imaging. Radiation exposure carries a risk of teratogenesis, particularly during the first trimester. The fetal radiation dose from a typical study is low (less than 5 mGy), which is below the threshold for deterministic effects. However, the stochastic risk of childhood cancer is increased, and the procedure is generally avoided in pregnancy unless the benefit outweighs the risk. Second and third trimester exposure poses lower risk for congenital malformations but still carries potential for later carcinogenesis. |
| Fetal Monitoring | Fetal radiation dose calculation should be performed for pregnant patients. Confirm pregnancy status before administration. Vital signs and fetal heart rate monitoring are not routinely required but may be considered if maternal condition warrants. No specific antidote or additional monitoring for the radiotracer itself is needed. |
| Fertility Effects | No known direct effects on fertility in humans from diagnostic use of Xenon Xe 133. Radiation doses from a single procedure are far below those associated with gonadal toxicity. Theoretical risk of stochastic damage to germ cells exists but is negligible at diagnostic levels. |
| Xenon Xe 133-V.S.S. is a radiopharmaceutical used for pulmonary ventilation imaging. Key tip: Administer via closed delivery system to minimize environmental exposure. Single-use vial; do not reuse. Monitor patient for bronchospasm in severe COPD. Use in pediatrics requires weight-based dose adjustment. Dispose properly per radioactive waste protocols. |
| Patient Advice | This is a radioactive drug used to image lung ventilation. · You will inhale the gas through a mask or mouthpiece. · Minimal radiation exposure; benefits outweigh risks. · No special diet or preparation needed. · Inform your doctor if you are pregnant, breastfeeding, or have severe lung disease. · You may experience transient dizziness or cough during inhalation. |